Carlos L. Arteaga, M.D.

Donna S. Hall Chair in Breast Cancer

Professor of Medicine


Division

Hematology/Oncology

Education:

M.D. - U of Guayaquil, Ecuador-1980

Training:

Fellowship

University of Texas Health Science Center at San Antonio


Office Address:
777 PRB (6307), Nashville, TN 37232-6307

Carlos L. Arteaga, M.D.

 Brief Bio

Carlos L. Arteaga obtained his M.D. degree with honors in 1980 at the Facultad the Ciencias Médicas of the University of Guayaquil in Guayaquil, Ecuador. He trained in Internal Medicine and Medical Oncology at Emory University (Atlanta, GA) and the University of Texas Health Sciences Center in San Antonio, TX, respectively. He joined Vanderbilt in 1989 where he now holds the Donna S. Hall Chair in Breast Cancer Research and serves as Professor of Medicine and Cancer Biology. Dr. Arteaga is also Associate Director for Translational/Clinical Research at the Vanderbilt-Ingram Cancer Center (VICC) where he leads the Breast Cancer Program and the recently founded Center for Cancer Targeted Therapies. He has over 250 publications in the areas of signaling by growth factor receptors and oncogenes in breast tumor cells, development of targeted therapies and biomarkers of drug action or resistance in breast cancer, and investigator-initiated clinical trials. His work includes the first demonstration that blockade of IGF-I receptor results in an antitumor effect in breast cancer; the first observation that tumor-host TGFb-mediated interactions are critical for breast tumor establishment and metastatic progression, thus providing a basis for the targeting of TGFb in cancers with a therapeutic intent; one of the first observations that loss of tumor suppressor PTEN confers resistance to ERBB receptor-targeted therapies; the role of p27 haploinsufficiency in breast cancer progression; and the role of PI3K signaling on resistance to antiestrogens in breast cancer.

Since 2002, he has directed the NCI-funded Vanderbilt Breast Cancer Specialized Program of Research Excellence (SPORE) where he co-leads several investigator-initiated clinical trials. He is funded by the National Cancer Institute, the American Cancer Society, the Department of Defense Breast Cancer Research Program, Stand Up 2 Cancer (SU2C) and the Susan G. Komen for the Cure and Breast Cancer Research Foundations. He is a member of the American Society of Clinical Investigation (1998) and the Association of American Physicians (2005). He served as member of the Experimental Therapeutics-2 NIH Study Section (1998-2003), the NCI Board of Scientific Counselors (1999-2004), NCI Parent Subcommittee A for review of Cancer Centers (2004-2008), the Breast Core Committee of the Eastern Cooperative Oncology Group (ECOG), and the Board of Directors of the American Association for Cancer Research (2004-2007). He co-chaired the former Developmental Therapeutics Committee of ECOG and chaired the AACR Special Conferences Committee (2002-2008). Arteaga is the recipient of the 2003 AACR Richard & Hinda Rosenthal Award, the 2007-2017 ACS Clinical Research Professor Award, the 2009 Gianni Bonadonna Award from the American Society of Clinical Oncology (ASCO) and the 2011 Brinker Award for Scientific Distinction from the Susan G. Komen for the Cure Foundation. As of this year, he serves in the Scientific Advisory Board of the Susan G. Komen for tehe Cure Breast Cancer Foundation. He co-chaired the AACR Special Conference ‘Advances in Breast Cancer Research’ in 2003, 2005, 2007, 2009 and 2013. He has served as AACR co-chair of the annual San Antonio Breast Cancer Symposium since 2009. He is Deputy Editor of Clinical Cancer Research and member of the Editorial Board of Cancer Cell and six other peer-reviewed journals. He serves on the advisory boards of several NCI Breast Cancer Research Programs and NCI-designated Cancer Centers. In 2013, he was elected as President Elect of the American Association for Cancer Research.

Administrative Contact Information 
Vanderbilt-Ingram Cancer Center  
683 Preston Research Building  
Nashville, TN  37232  
Phone:  615-936-3524  
Fax:  615-343-1790

Administrative Assistant: Pamela Johnson
email:pamela.johnson@vanderbilt.edu

 


Research Focus:

Research Description 

Research Specialty

- Oncogene signaling in breast development/transformation and breast cancer progression.

- Mechanisms of resistance to targeted therapies in breast cancer.

- Novel clinical trials in breast cancer.

Phone No. 

6-3524, 6-1919

Research Keywords 

breast cancer, mammary gland development, erbB receptor tyrosine kinases, TGF-beta, p27, transgenic mice, proteomics, signal transduction, oncogenes

publications 

Polosukhina D, Love HD, Correa H, Su Z, Dahlman KB, Pao W, Moses HL, Arteaga CL, Lovvorn HN, Zent R, Clark PE. Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms Tumors. Mol Oncol [print-electronic]. 2017 Feb 2/11/2017; PMID: 28188683, DOI: 10.1002/1878-0261.12044, ISSN: 1878-0261. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28188683., 2017.

Jansen VM, Bhola NE, Bauer JA, Formisano L, Lee KM, Hutchinson KE, Witkiewicz AK, Moore PD, Estrada MV, Sanchez V, Ericsson PG, Sanders M, Pohlmann PR, Pishvaian MJ, Riddle DA, Wei W, Dugger TC, Knudsen E, Arteaga CL. Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer. Cancer Res [print-electronic]. 2017 Mar 3/1/2017; PMID: 28249908, PII: 0008-5472.CAN-16-2653, DOI: 10.1158/0008-5472.CAN-16-2653, ISSN: 1538-7445. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28249908., 2017.

Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV, Sánchez V, Sanders ME, Cook RS, Pilkinton MA, Mallal SA, Wang K, Miller VA, Stephens PJ, Yelensky R, Doimi FD, Gómez H, Ryzhov SV, Darcy PK, Arteaga CL, Balko JM. RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. Clin. Cancer Res [print-electronic]. 2016 Mar 3/15/2016; 22(6): 1499-509. PMID: 26515496, PMCID: PMC4794351, PII: 1078-0432.CCR-15-1125, DOI: 10.1158/1078-0432.CCR-15-1125, ISSN: 1078-0432. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26515496., 2016.

Bhola NE, Jansen VM, Bafna S, Giltnane JM, Balko JM, Estrada MV, Meszoely I, Mayer I, Abramson V, Ye F, Sanders M, Dugger TC, Allen EV, Arteaga CL. Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer. Cancer Res [print-electronic]. 2015 Jan 1/15/2015; 75(2): 405-14. PMID: 25480943, PMCID: PMC4297507, PII: 0008-5472.CAN-14-2475, DOI: 10.1158/0008-5472.CAN-14-2475, ISSN: 1538-7445. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25480943., 2015.

Walsh AJ, Cook RS, Lee JH, Arteaga CL, Skala MC. Collagen density and alignment in responsive and resistant trastuzumab-treated breast cancer xenografts. J Biomed Opt. 2015 Feb; 20(2): 26004. PMID: 25700233, PMCID: PMC4335617, PII: 2173302, DOI: 10.1117/1.JBO.20.2.026004, ISSN: 1560-2281. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25700233., 2015.

Whisenant JG, McIntyre JO, Peterson TE, Kang H, Sánchez V, Manning HC, Arteaga CL, Yankeelov TE. Utility of [18¿F]FLT-PET to assess treatment response in trastuzumab-resistant and trastuzumab-sensitive HER2-overexpressing human breast cancer xenografts. Mol Imaging Biol. 2015 Feb; 17(1): 119-28. PMID: 25034624, PMCID: PMC4311727, DOI: 10.1007/s11307-014-0770-z, ISSN: 1860-2002. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25034624., 2015.

Ju JH, Oh S, Lee KM, Yang W, Nam KS, Moon HG, Noh DY, Kim CG, Park G, Park JB, Lee T, Arteaga CL, Shin I. Cytokeratin19 induced by HER2/ERK binds and stabilizes HER2 on cell membranes. Cell Death Differ [print-electronic]. 2015 Apr; 22(4): 665-76. PMID: 25342465, PMCID: PMC4356337, PII: cdd2014155, DOI: 10.1038/cdd.2014.155, ISSN: 1476-5403. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25342465., 2015.

Abramson RG, McGhee CR, Lakomkin N, Arteaga CL. Pitfalls in RECIST Data Extraction for Clinical Trials: Beyond the Basics. Acad Radiol [print-electronic]. 2015 Jun; 22(6): 779-86. PMID: 25794800, PMCID: PMC4429002, PII: S1076-6332(15)00051-3, DOI: 10.1016/j.acra.2015.01.015, ISSN: 1878-4046. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25794800., 2015.

Dillon LM, Bean JR, Yang W, Shee K, Symonds LK, Balko JM, McDonald WH, Liu S, Gonzalez-Angulo AM, Mills GB, Arteaga CL, Miller TW. P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer. Oncogene [print-electronic]. 2015 Jul 7/23/2015; 34(30): 3968-76. PMID: 25284585, PMCID: PMC4387124, PII: onc2014328, DOI: 10.1038/onc.2014.328, ISSN: 1476-5594. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25284585., 2015.

Stricker T, Arteaga CL. Drug-Resistant Brain Metastases: A Role for Pharmacology, Tumor Evolution, and Too-Late Therapy. Cancer discovery. 2015 Nov; 5(11) Sect. 1124,6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26526693., 2015.

Bi X, Rexer B, Arteaga CL, Guo M, Mahadevan-Jansen A. Evaluating HER2 amplification status and acquired drug resistance in breast cancer cells using Raman spectroscopy. J Biomed Opt. 2014 Feb; 19(2): 25001. PMID: 24496495, PMCID: PMC3913568, PII: 1828548, DOI: 10.1117/1.JBO.19.2.025001, ISSN: 1560-2281. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24496495., 2014.

Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sánchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, Gómez H, Horiuchi D, Goga A, Lehmann BD, Bauer JA, Pietenpol JA, Ross JS, Palmer GA, Yelensky R, Cronin M, Miller VA, Stephens PJ, Arteaga CL. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov [print-electronic]. 2014 Feb; 4(2): 232-45. PMID: 24356096, PMCID: PMC3946308, PII: 2159-8290.CD-13-0286, DOI: 10.1158/2159-8290.CD-13-0286, ISSN: 2159-8290. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24356096., 2014.

Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell. 2014 Mar 3/17/2014; 25(3): 282-303. PMID: 24651011, PMCID: PMC4018830, PII: S1535-6108(14)00086-5, DOI: 10.1016/j.ccr.2014.02.025, ISSN: 1878-3686. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24651011., 2014.

Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Gonzalez-Angulo AM, Ferrer-Lozano J, Perez-Fidalgo JA, Cristofanilli M, Gómez H, Arteaga CL, Giltnane J, Balko JM, Cronin MT, Jarosz M, Sun J, Hawryluk M, Lipson D, Otto G, Ross JS, Dvir A, Soussan-Gutman L, Wolf I, Rubinek T, Gilmore L, Schnitt S, Come SE, Pusztai L, Stephens P, Brown M, Miller VA. Emergence of constitutively active estrogen receptor-a mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin. Cancer Res [print-electronic]. 2014 Apr 4/1/2014; 20(7): 1757-67. PMID: 24398047, PMCID: PMC3998833, PII: 1078-0432.CCR-13-2332, DOI: 10.1158/1078-0432.CCR-13-2332, ISSN: 1078-0432. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24398047., 2014.

Mayer IA, Abramson VG, Isakoff SJ, Forero A, Balko JM, Kuba MG, Sanders ME, Yap JT, Van den Abbeele AD, Li Y, Cantley LC, Winer E, Arteaga CL. Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol [print-electronic]. 2014 Apr 4/20/2014; 32(12): 1202-9. PMID: 24663045, PMCID: PMC3986383, PII: JCO.2013.54.0518, DOI: 10.1200/JCO.2013.54.0518, ISSN: 1527-7755. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24663045., 2014.

Abramson VG, Cooper Lloyd M, Ballinger T, Sanders ME, Du L, Lai D, Su Z, Mayer I, Levy M, LaFrance DR, Vnencak-Jones CL, Shyr Y, Dahlman KB, Pao W, Arteaga CL. Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling. Breast Cancer Res. Treat [print-electronic]. 2014 Jun; 145(2): 389-99. PMID: 24722917, PMCID: PMC4046906, DOI: 10.1007/s10549-014-2945-3, ISSN: 1573-7217. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24722917., 2014.

Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, Keedy VL, Reddy NM, Arteaga CL, Sosman JA, Pao W. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist [print-electronic]. 2014 Jun; 19(6): 616-22. PMID: 24797823, PMCID: PMC4041676, PII: theoncologist.2014-0011, DOI: 10.1634/theoncologist.2014-0011, ISSN: 1549-490X. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24797823., 2014.

McCormack DR, Walsh AJ, Sit W, Arteaga CL, Chen J, Cook RS, Skala MC. In vivo hyperspectral imaging of microvessel response to trastuzumab treatment in breast cancer xenografts. Biomed Opt Express. 2014 Jul 7/1/2014; 5(7): 2247-61. PMID: 25071962, PMCID: PMC4102362, PII: 210394, DOI: 10.1364/BOE.5.002247, ISSN: 2156-7085. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25071962., 2014.

Walsh AJ, Cook RS, Sanders ME, Aurisicchio L, Ciliberto G, Arteaga CL, Skala MC. Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer. Cancer Res [print-electronic]. 2014 Sep 9/15/2014; 74(18): 5184-94. PMID: 25100563, PMCID: PMC4167558, PII: 0008-5472.CAN-14-0663, DOI: 10.1158/0008-5472.CAN-14-0663, ISSN: 1538-7445. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25100563., 2014.

Liu S, Meng X, Chen H, Liu W, Miller T, Murph M, Lu Y, Zhang F, Gagea M, Arteaga CL, Mills GB, Meric-Bernstam F, González-Angulo AM. Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer. Oncotarget. 2014 Oct 10/15/2014; 5(19): 9049-64. PMID: 24979294, PMCID: PMC4253418, PII: 2022, DOI: 10.18632/oncotarget.2022, ISSN: 1949-2553. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24979294., 2014.

Castaneda CA, Lopez-Ilasaca M, Pinto JA, Chirinos-Arias M, Doimi F, Neciosup SP, Rojas KI, Vidaurre T, Balko JM, Arteaga CL, Gomez HL. PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers. Hematol Oncol Stem Cell Ther [print-electronic]. 2014 Dec; 7(4): 142-8. PMID: 25467032, PII: S1658-3876(14)00084-3, DOI: 10.1016/j.hemonc.2014.09.007, ISSN: 1658-3876. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25467032., 2014.

View More Publications

Fellowship 

University of Texas Health Science Center at San Antonio

residency 

Emory University